Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00027586
Status:
COMPLETED
Last Update Posted:
2018-10-31
First Post:
2001-12-07
Brief Title:
Imatinib Mesylate in Treating Patients With Metastatic Melanoma
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
Phase II Trial of Gleevec Imatinib Mesylate STI-571 in Metastatic Melanoma
Status:
COMPLETED
Status Verified Date:
2018-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma
PURPOSE Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic melanoma
PURPOSE Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic melanoma
Detailed Description:
OBJECTIVES
Determine the clinical activity of imatinib mesylate STI571 in patients with metastatic melanoma
Determine the side effects of this drug in these patients
Correlate molecular studies with responsiveness to this drug in these patients
OUTLINE Patients receive oral imatinib mesylate STI571 twice daily Treatment continues in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A total of 21-78 patients will be accrued for this study within 6-15 months
Determine the clinical activity of imatinib mesylate STI571 in patients with metastatic melanoma
Determine the side effects of this drug in these patients
Correlate molecular studies with responsiveness to this drug in these patients
OUTLINE Patients receive oral imatinib mesylate STI571 twice daily Treatment continues in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A total of 21-78 patients will be accrued for this study within 6-15 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P30CA016672 | NIH | None | None |
| MDA-ID-01284 | OTHER | None | None |
| NCI-5345 | None | None | None |
| CDR0000069045 | REGISTRY | NCI PDQ | httpsreporternihgovquickSearchP30CA016672 |